Related Experiment Videos
Surgery for locally recurrent rectal cancer.
T Wiggers1, G H H Mannaerts, A W K S Marinelli
1Department of Surgical Oncology, Groningen University Hospital, PO Box 30.001, 9700 RB Groningen, the Netherlands. t.wiggers@chir.azg.nl
Summary
Multimodality treatment for recurrent rectal cancer, including pre-operative radiation and surgery, achieved a 60% three-year survival rate. Chemotherapy as a radiosensitizer improved R0 resection rates, crucial for better patient outcomes.
Area of Science:
- Oncology
- Surgical Oncology
- Radiation Oncology
Background:
- Locally recurrent rectal cancer requires accurate staging for treatment planning.
- Multimodality treatment is standard for achieving microscopically tumor-free margins (R0 resection).
Purpose of the Study:
- To evaluate the effectiveness of a multimodality treatment approach for locally recurrent rectal cancer.
- To assess the impact of chemotherapy as a radiosensitizer on R0 resection rates.
Main Methods:
- Diagnosis involved imaging to assess tumor extent and metastases.
- Treatment comprised pre-operative radiation, extended resection, and intra-operative radiotherapy (electron beam or brachytherapy).
- Chemotherapy was used as a radiosensitizer in some cases.
Main Results:
- The multimodality treatment resulted in a 60% three-year survival rate and 73% local control in 33 patients.
- Adding chemotherapy as a radiosensitizer increased R0 resections by 20%.
- Challenges include radiotherapy toxicity and tissue scarring, complicating tumor assessment.
Conclusions:
- Multimodality treatment offers a survival benefit for recurrent rectal cancer.
- Chemotherapy can enhance R0 resection rates, improving treatment efficacy.
- Future improvements lie in careful patient selection, surgeon expertise, and optimized pre-operative radiotherapy.